U.S. markets closed

Ekso Bionics Holdings, Inc. (EKSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4200+0.0200 (+0.83%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close2.4000
Bid2.3300 x 2200
Ask2.4500 x 900
Day's Range2.3801 - 2.4900
52 Week Range1.5350 - 5.1740
Avg. Volume605,034
Market Cap31.524M
Beta (5Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-0.9260
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EKSO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ekso Bionics Holdings, Inc.
    Analyst Report: Parker-Hannifin CorporationParker Hannifin is an industrial conglomerate operating two segments: diversified industrial, which serves a variety of end markets, and aerospace systems, which sells engine and actuation components. The diversified industrial segment consists of six groups, including engineered materials (sealing devices), filtration (filters and systems monitoring and removing contaminants from liquids and gases), fluid connectors (valves, couplings, and other fittings), instrumentation (flow manufacturing components and fluid control applications), and motion systems (hydraulic, pneumatic, and electromechanical components in industrial machinery and equipment). The segment boasts 15,500 independent distributors, and about 40% of its business occurs outside the United States.
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
  • Zacks

    Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

    Ekso Bionics (EKSO) delivered earnings and revenue surprises of 4.17% and 0.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Ekso Bionics Reports Second Quarter 2022 Results

    RICHMOND, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2022. Recent Highlights and Accomplishments Reported revenue of $3.5 million in the second quarter of 2022, an increase of 57% year-over-yearReceived 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market EksoNR for use w

  • GlobeNewswire

    Ekso Bionics to Report Second Quarter 2022 Financial Results on July 28

    RICHMOND, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2022 after the close of trading on Thursday, July 28, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcas